Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study

被引:8
|
作者
Bae, Charles J. [1 ]
Zee, Phyllis C. [2 ]
Leary, Eileen B. [3 ]
Fuller, Douglas S. [4 ]
Macfadden, Wayne [4 ,6 ]
Candler, Shawn [4 ]
Steininger, Teresa L. [3 ]
Husain, Aatif M. [5 ]
机构
[1] Univ Penn, Penn Med, Philadelphia, PA USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Jazz Pharmaceut, Palo Alto, CA USA
[4] Jazz Pharmaceut, Philadelphia, PA USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] 2005 Market St, Philadelphia, PA 19103 USA
关键词
Narcolepsy; Excessive daytime sleepiness; Epworth Sleepiness Scale; Cataplexy; Sodium oxybate; Low -sodium oxybate; BLOOD-PRESSURE; WITHDRAWAL; BURDEN;
D O I
10.1016/j.sleep.2023.05.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB). Methods: TENOR is a patient-centric, prospective, observational, virtual-format study. Participants were adults with narcolepsy (type 1 or 2) who were transitioning from SXB to LXB treatment (& PLUSMN;7 days from LXB initiation). Effectiveness and tolerability data were collected online from baseline (taking SXB) through 21 weeks (taking LXB) via daily and weekly diaries and questionnaires, including the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and the British Columbia Cognitive Complaints Inventory (BC-CCI). Results: TENOR participants (N = 85) were 73% female with a mean (SD) age of 40.3 (13.0) years. Mean (SD) ESS scores decreased numerically throughout the transition from SXB to LXB (baseline: 9.9 [5.2]; week 21: 7.5 [4.7]), with 59.5% and 75.0% of participants having scores in the normal range (& LE;10) at baseline and week 21, respectively. Mean (SD) FOSQ-10 scores (baseline: 14.4 [3.4]; week 21: 15.2 [3.2]) and BC-CCI scores (baseline: 6.1 [4.4]; week 21: 5.0 [4.3]) also remained stable. The most common symptoms related to tolerability reported by participants at baseline were sleep inertia, hyperhidrosis, and dizziness (45.2%, 40.5%, and 27.4%, respectively), which decreased in prevalence by week 21 (33.8%, 13.2%, and 8.8%, respectively). Conclusions: Findings from TENOR confirm maintenance of effectiveness and tolerability when transitioning from SXB to LXB treatment. & COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:65 / 74
页数:10
相关论文
共 29 条
  • [21] Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
    Calabrese, Laura
    Cinotti, Elisa
    D'onghia, Martina
    Cartocci, Alessandra
    Rubegni, Pietro
    Maccari, Francois
    Boulard, Claire
    Reguiai, Ziad
    Becherel, Pierre Andre
    Jacobzone, Caroline
    Begon, Edouard
    Fite, Charlotte
    Walls, Beatrice
    Liegeon, Anne Laure
    Parier, Josiane
    Chaby, Guillaume
    Perrot, Jean-Luc
    ACTA DERMATO-VENEREOLOGICA, 2025, 105
  • [22] Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study
    Fu, Donglin
    Li, Li
    Li, Yifan
    Liu, Xiaofei
    Chen, Hongkang
    Wu, Naitian
    Sun, Guangfeng
    BMC SURGERY, 2022, 22 (01)
  • [23] Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)
    Al-Lehebi, Riyad Omar
    Al Ahmad, Mona
    Maturu, Venkata Nagarjuna
    Mesa, Alejandra Galeano
    Mahboub, Bassam
    Garcia, Elizabeth
    Fernandez, Patricia
    Soares, Claudia
    Abreu, Gabriela
    dos Santos, Debora
    Queiroz, Juliana
    Raimondi, Alejandro
    Laucho-Contreras, Maria
    Noibi, Saeed
    Levy, Gur
    Bavbek, Sevim
    ADVANCES IN THERAPY, 2024, 41 (11) : 4008 - 4031
  • [24] Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study
    Anderson, John
    Soteres, Daniel
    Mellor, Jennifer
    Connolly, Hannah
    Chem, M.
    Wynne-Cattanach, Kieran
    Earl, Lucy
    Schultz, Bob G.
    Juethner, Salome
    ALLERGY AND ASTHMA PROCEEDINGS, 2024, 45 (04) : 247 - 254
  • [25] Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records
    Mohammed Yunus Khan
    Sucheta Pandit
    Jabir Abdulkutty
    Girish Navasundi
    Prakash Kumar Hazra
    Uday Phadke
    Amey Mane
    Suyog Mehta
    Snehal Shah
    Cardiology and Therapy, 2021, 10 : 255 - 269
  • [26] Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records
    Khan, Mohammed Yunus
    Pandit, Sucheta
    Abdulkutty, Jabir
    Navasundi, Girish
    Hazra, Prakash Kumar
    Phadke, Uday
    Mane, Amey
    Mehta, Suyog
    Shah, Snehal
    CARDIOLOGY AND THERAPY, 2021, 10 (01) : 255 - 269
  • [27] Feasibility of a psychoeducational family intervention for people with bipolar I disorder and their relatives: Results from an Italian real-world multicentre study
    Fiorillo, A.
    Del Vecchio, V.
    Luciano, M.
    Sampogna, G.
    Sbordone, D.
    Catapano, F.
    De Rosa, C.
    Malangone, C.
    Tortorella, A.
    Veltro, F.
    Nicolo, G.
    Piselli, M.
    Bardicchia, F.
    Ciampini, G.
    Lampis, D.
    Moroni, A.
    Bassi, M.
    Iapichino, S.
    Biondi, S.
    Graziani, A.
    Orlandi, E.
    Starace, F.
    Baronessa, C.
    Carra, G.
    Maj, M.
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 190 : 657 - 662
  • [28] Real-world data from Europe and Africa suggest that accuracy of systems for self-monitoring of blood glucose is frequently impaired by low hematocrit
    Hinzmann, Rolf
    Militz, Daniel
    Zima, Tomas
    Spacek, Martin
    Storm, Huib
    Chapanduka, Zivanai
    Hauss, Oliver
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 177
  • [29] Real-world cross-comparison of metabolic outcomes with different sodium-glucose co-transporter 2 inhibitors agents in adults with type 2 diabetes: results from the Association of British Clinical Diabetologists audit programme
    Crabtree, Thomas sj
    Bickerton, Alex
    Dhatariya, Ketan
    Gallagher, Alison
    Elliott, Jackie
    Adamson, Karen
    Gallen, Ian
    Barnes, Dennis
    Sivappriyan, Siva
    Idris, Iskander
    Ryder, Robert ej
    Contributors, On behalf of all sgltiaudit
    BRITISH JOURNAL OF DIABETES, 2024, 24 (01): : 51 - +